Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 May;25(4):325-8.
doi: 10.1002/dmrr.943.

C-peptide in the natural history of type 1 diabetes

Jerry P Palmer  1
Affiliations
Review

C-peptide in the natural history of type 1 diabetes

Jerry P Palmer. Diabetes Metab Res Rev. 2009 May.

Abstract

Type 1 diabetes is diagnosed when the patient's endogenous insulin secretion decreases to a level which results in hyperglycemia. After diagnosis, insulin secretion continues to decline. As a reference for clinical trials trying to preserve endogenous beta-cell function in patients with recently diagnosed type 1 diabetes, in this short review I attempt to summarize the natural history of endogenous beta-cell function after the diagnosis of type 1 diabetes.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Rate of Change of Peak C-Peptide over Peri-Onset period
Rates of change in peak C-peptide in the perionset period. Shown are the rates of change of peak C-peptide levels according to intervals before and after diagnosis. C-peptide levels changed minimally between~12 and 6 months before diagnosis. There was a decline in the 6 months before diagnosis. There was a decline in the 6 months before diagnosis that was more substantial in the period after diagnosis.
See this image and copyright information in PMC

References

    1. Black MB, Rosenfield RL, Mako ME, Steiner DF, Rubenstein AH. Sequential changes in beta-cell function in insulin-treated diabetic patients assessed by c-peptide immunoreactivity. N Engl J Med. 1973;288:1144–1148. - PubMed
    1. Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS Diabetes Prevention Trial-1 Study Group. Patterns of metabolic progression to type 1 diabetes in the diabetes prevention trial-type 1. Diabetes Care. 2006;29:643–649. - PubMed
    1. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer JP, Cuthbertson D, Matheson D, Skyler JS. Glucose and c-peptide changes in the peri-onset period of type 1 diabetes in the diabetes prevention trial-type 1. Diabetes Care. 2008;31:2188–2192. - PMC - PubMed
    1. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function. Diabetes. 2004;53:250–264. - PubMed
    1. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual β-cell function in patients with type 1 diabetes in the diabetes control and complications trial. Ann Intern Med. 1998;128:517–523. - PubMed

Publication types

MeSH terms